TherapeuticsMD, Inc. (TXMD)
USD 1.03
(4.06%)
USD 1.03
(4.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.02 Million USD | -74.65% |
| 2022 | 55.31 Million USD | -78.98% |
| 2021 | 263.09 Million USD | -13.91% |
| 2020 | 305.61 Million USD | 19.01% |
| 2019 | 256.78 Million USD | 124.34% |
| 2018 | 114.45 Million USD | 759.23% |
| 2017 | 13.32 Million USD | -11.09% |
| 2016 | 14.98 Million USD | 40.47% |
| 2015 | 10.66 Million USD | -0.23% |
| 2014 | 10.69 Million USD | 46.08% |
| 2013 | 7.31 Million USD | 0.92% |
| 2012 | 7.25 Million USD | 130.16% |
| 2011 | 3.15 Million USD | 129.14% |
| 2010 | 1.37 Million USD | 18.45% |
| 2009 | 1.16 Million USD | 3149.59% |
| 2008 | 35.72 Thousand USD | -54.1% |
| 2007 | 77.82 Thousand USD | -56.72% |
| 2006 | 179.82 Thousand USD | -63.54% |
| 2005 | 493.18 Thousand USD | 1228.79% |
| 2004 | 37.11 Thousand USD | 15.59% |
| 2003 | 32.1 Thousand USD | 91.08% |
| 2002 | 16.8 Thousand USD | -27.06% |
| 2001 | 23.03 Thousand USD | 42.16% |
| 2000 | 16.2 Thousand USD | -9.0% |
| 1999 | 17.8 Thousand USD | -64.89% |
| 1998 | 50.72 Thousand USD | 626.39% |
| 1997 | 6983.00 USD | 44.76% |
| 1996 | 4824.00 USD | -92.52% |
| 1995 | 64.49 Thousand USD | 462.21% |
| 1994 | 11.47 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 13.42 Million USD | -4.26% |
| 2024 Q2 | 12.45 Million USD | -7.21% |
| 2023 Q2 | 22.49 Million USD | -18.44% |
| 2023 FY | 14.02 Million USD | -74.65% |
| 2023 Q1 | 27.57 Million USD | -50.15% |
| 2023 Q3 | 22.44 Million USD | -0.23% |
| 2023 Q4 | 14.02 Million USD | -37.52% |
| 2022 Q4 | 55.31 Million USD | -69.64% |
| 2022 Q3 | 182.17 Million USD | 5.75% |
| 2022 Q2 | 172.26 Million USD | -37.12% |
| 2022 FY | 55.31 Million USD | -78.98% |
| 2022 Q1 | 273.96 Million USD | 4.13% |
| 2021 Q2 | 259.67 Million USD | 4.38% |
| 2021 FY | 263.09 Million USD | -13.91% |
| 2021 Q3 | 266.98 Million USD | 2.82% |
| 2021 Q1 | 248.78 Million USD | -18.59% |
| 2021 Q4 | 263.09 Million USD | -1.46% |
| 2020 Q2 | 299.62 Million USD | -4.53% |
| 2020 Q1 | 313.84 Million USD | 22.22% |
| 2020 Q3 | 293.32 Million USD | -2.1% |
| 2020 Q4 | 305.61 Million USD | 4.19% |
| 2020 FY | 305.61 Million USD | 19.01% |
| 2019 Q2 | 238.45 Million USD | 96.75% |
| 2019 FY | 256.78 Million USD | 124.34% |
| 2019 Q1 | 121.19 Million USD | 5.89% |
| 2019 Q4 | 256.78 Million USD | -5.31% |
| 2019 Q3 | 271.19 Million USD | 13.73% |
| 2018 Q2 | 94.35 Million USD | 502.53% |
| 2018 Q3 | 102.53 Million USD | 8.67% |
| 2018 Q4 | 114.45 Million USD | 11.63% |
| 2018 Q1 | 15.65 Million USD | 17.55% |
| 2018 FY | 114.45 Million USD | 759.23% |
| 2017 FY | 13.32 Million USD | -11.09% |
| 2017 Q4 | 13.32 Million USD | 22.48% |
| 2017 Q1 | 14.08 Million USD | -5.98% |
| 2017 Q2 | 13.28 Million USD | -5.67% |
| 2017 Q3 | 10.87 Million USD | -18.15% |
| 2016 FY | 14.98 Million USD | 40.47% |
| 2016 Q1 | 9.59 Million USD | -10.03% |
| 2016 Q2 | 9.33 Million USD | -2.68% |
| 2016 Q3 | 12.46 Million USD | 33.5% |
| 2016 Q4 | 14.98 Million USD | 20.17% |
| 2015 Q2 | 12.67 Million USD | 7.71% |
| 2015 Q3 | 12.9 Million USD | 1.8% |
| 2015 Q4 | 10.66 Million USD | -17.33% |
| 2015 Q1 | 11.76 Million USD | 10.06% |
| 2015 FY | 10.66 Million USD | -0.23% |
| 2014 Q2 | 6.94 Million USD | 1.88% |
| 2014 FY | 10.69 Million USD | 46.08% |
| 2014 Q1 | 6.81 Million USD | -6.82% |
| 2014 Q3 | 11 Million USD | 58.44% |
| 2014 Q4 | 10.69 Million USD | -2.88% |
| 2013 Q4 | 7.31 Million USD | 14.52% |
| 2013 FY | 7.31 Million USD | 0.92% |
| 2013 Q3 | 6.39 Million USD | 38.95% |
| 2013 Q2 | 4.59 Million USD | 8.22% |
| 2013 Q1 | 4.24 Million USD | -41.39% |
| 2012 Q2 | 5.58 Million USD | 15.33% |
| 2012 FY | 7.25 Million USD | 130.16% |
| 2012 Q1 | 4.84 Million USD | 53.63% |
| 2012 Q3 | 7.84 Million USD | 40.6% |
| 2012 Q4 | 7.25 Million USD | -7.61% |
| 2011 FY | 3.15 Million USD | 129.14% |
| 2011 Q4 | 3.15 Million USD | 620.88% |
| 2011 Q3 | 437.04 Thousand USD | 22.55% |
| 2011 Q2 | 356.63 Thousand USD | 20.85% |
| 2011 Q1 | 295.1 Thousand USD | -78.54% |
| 2010 Q2 | 2.34 Million USD | 56.46% |
| 2010 FY | 1.37 Million USD | 18.45% |
| 2010 Q3 | 1.35 Million USD | -42.04% |
| 2010 Q4 | 1.37 Million USD | 1.2% |
| 2010 Q1 | 1.49 Million USD | 29.07% |
| 2009 FY | 1.16 Million USD | 3149.59% |
| 2009 Q3 | 534.65 Thousand USD | 1541.24% |
| 2009 Q2 | 32.57 Thousand USD | -14.92% |
| 2009 Q4 | 1.16 Million USD | 117.12% |
| 2009 Q1 | 38.28 Thousand USD | 7.19% |
| 2008 Q2 | 44.5 Thousand USD | -47.08% |
| 2008 Q1 | 84.11 Thousand USD | 8.08% |
| 2008 FY | 35.72 Thousand USD | -54.1% |
| 2008 Q4 | 35.72 Thousand USD | 7.38% |
| 2008 Q3 | 33.26 Thousand USD | -25.26% |
| 2007 Q3 | 136.27 Thousand USD | 16.14% |
| 2007 Q1 | 183.03 Thousand USD | 1.78% |
| 2007 Q2 | 117.34 Thousand USD | -35.89% |
| 2007 FY | 77.82 Thousand USD | -56.72% |
| 2007 Q4 | 77.82 Thousand USD | -42.89% |
| 2006 Q4 | 179.82 Thousand USD | -32.77% |
| 2006 Q3 | 267.48 Thousand USD | 11.56% |
| 2006 FY | 179.82 Thousand USD | -63.54% |
| 2006 Q2 | 239.77 Thousand USD | 35.92% |
| 2006 Q1 | 176.4 Thousand USD | -64.23% |
| 2005 Q4 | 493.18 Thousand USD | 211.27% |
| 2005 Q1 | 57.44 Thousand USD | 54.79% |
| 2005 FY | 493.18 Thousand USD | 1228.79% |
| 2005 Q3 | 158.44 Thousand USD | 228.41% |
| 2005 Q2 | 48.24 Thousand USD | -16.02% |
| 2004 Q3 | 73.46 Thousand USD | 85.02% |
| 2004 Q1 | 40.33 Thousand USD | 25.61% |
| 2004 Q2 | 39.7 Thousand USD | -1.55% |
| 2004 FY | 37.11 Thousand USD | 15.59% |
| 2004 Q4 | 37.11 Thousand USD | -49.48% |
| 2003 Q3 | 26.31 Thousand USD | 5.68% |
| 2003 Q4 | 32.1 Thousand USD | 22.04% |
| 2003 Q2 | 24.89 Thousand USD | -49.38% |
| 2003 Q1 | 49.18 Thousand USD | 192.7% |
| 2003 FY | 32.1 Thousand USD | 91.08% |
| 2002 Q1 | 19.52 Thousand USD | -15.27% |
| 2002 Q4 | 16.8 Thousand USD | -8.27% |
| 2002 Q3 | 18.31 Thousand USD | 7.92% |
| 2002 Q2 | 16.97 Thousand USD | -13.05% |
| 2002 FY | 16.8 Thousand USD | -27.06% |
| 2001 Q4 | 23.03 Thousand USD | -28.6% |
| 2001 Q1 | 20.85 Thousand USD | 28.66% |
| 2001 FY | 23.03 Thousand USD | 42.16% |
| 2001 Q2 | 21.31 Thousand USD | 2.21% |
| 2001 Q3 | 32.26 Thousand USD | 51.42% |
| 2000 Q4 | 16.2 Thousand USD | -15.79% |
| 2000 Q3 | 19.24 Thousand USD | -12.28% |
| 2000 Q2 | 21.93 Thousand USD | -8.31% |
| 2000 Q1 | 23.92 Thousand USD | 34.35% |
| 2000 FY | 16.2 Thousand USD | -9.0% |
| 1999 Q4 | 17.8 Thousand USD | 0.0% |
| 1999 FY | 17.8 Thousand USD | -64.89% |
| 1998 FY | 50.72 Thousand USD | 626.39% |
| 1997 FY | 6983.00 USD | 44.76% |
| 1996 FY | 4824.00 USD | -92.52% |
| 1995 FY | 64.49 Thousand USD | 462.21% |
| 1994 FY | 11.47 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 98.521% |
| Embecta Corp. | 2.03 Billion USD | 99.311% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 97.027% |
| Dynavax Technologies Corporation | 375.02 Million USD | 96.261% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 97.878% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 98.009% |
| PainReform Ltd. | 2.69 Million USD | -421.07% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 91.445% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -128.386% |
| SCYNEXIS, Inc. | 55.45 Million USD | 74.712% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -52.469% |
| Cosmos Health Inc. | 30.25 Million USD | 53.65% |
| Journey Medical Corporation | 56.49 Million USD | 75.182% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -128.386% |
| Safety Shot Inc | 3.89 Million USD | -260.273% |
| Alpha Teknova, Inc. | 38.55 Million USD | 63.627% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 89.755% |
| Bright Green Corporation | 6.43 Million USD | -117.797% |
| Procaps Group, S.A. | 462.06 Million USD | 96.965% |
| Theratechnologies Inc. | 98.63 Million USD | 85.785% |
| Harrow Health, Inc. | 241.75 Million USD | 94.2% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -60.142% |
| Biofrontera Inc. | 23.13 Million USD | 39.401% |
| DURECT Corporation | 30.4 Million USD | 53.884% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 97.123% |
| Cronos Group Inc. | 43.73 Million USD | 67.94% |
| OptiNose, Inc. | 194.33 Million USD | 92.785% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 98.284% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 71.056% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 33.159% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 92.269% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -271.726% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 73.3% |
| Radius Health, Inc. | 804.29 Million USD | 98.257% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1.946% |
| ProPhase Labs, Inc. | 42.54 Million USD | 67.041% |
| Phibro Animal Health Corporation | 725.54 Million USD | 98.067% |
| Procaps Group S.A. | 462.06 Million USD | 96.965% |
| Alvotech | 1.88 Billion USD | 99.255% |
| Viatris Inc. | 27.21 Billion USD | 99.948% |
| Rockwell Medical, Inc. | 30.88 Million USD | 54.595% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 84.485% |
| SIGA Technologies, Inc. | 57.97 Million USD | 75.815% |
| Tilray Brands, Inc. | 892.11 Million USD | 98.428% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 93.621% |
| Shineco, Inc. | 47.6 Million USD | 70.543% |
| PetIQ, Inc. | 645.22 Million USD | 97.827% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -6287.806% |
| Incannex Healthcare Limited | 5.83 Million USD | -140.515% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 98.624% |
| Alimera Sciences, Inc. | 107.35 Million USD | 86.939% |
| Silver Spike Investment Corp. | 3 Million USD | -365.873% |
| Assertio Holdings, Inc. | 148.41 Million USD | 90.552% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -639.571% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 34.218% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -99.573% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -65.149% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 91.913% |
| Hempacco Co., Inc. | 18.82 Million USD | 25.504% |
| Talphera, Inc. | 6.29 Million USD | -122.925% |
| Alvotech | 1.88 Billion USD | 99.255% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 91.876% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 98.321% |
| Currenc Group, Inc. | 177.67 Million USD | 92.108% |
| Kamada Ltd. | 109.96 Million USD | 87.249% |
| Indivior PLC | 1.95 Billion USD | 99.281% |
| Evoke Pharma, Inc. | 9.64 Million USD | -45.335% |
| Flora Growth Corp. | 17.22 Million USD | 18.581% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -65.149% |
| Evolus, Inc. | 209.68 Million USD | 93.313% |
| HUTCHMED (China) Limited | 536.38 Million USD | 97.386% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 98.395% |
| Akanda Corp. | 12.66 Million USD | -10.681% |